Result of AGM, Warrants & Directorate Change
ValiRx PLC announced that all resolutions were passed at its Annual General Meeting, and the company has issued 577,500,000 Fundraising Warrants exercisable at 0.28 pence per Ordinary Share until the third anniversary of grant, along with 53,750,000 Broker Warrants exercisable at the Issue Price. Additionally, Non-Executive Director Cathy Tralau-Stewart stepped down from the Board, and Directors Mark Eccleston and Gerry Desler were notified of warrant transactions as part of the fundraising, with Eccleston receiving 25,000,000 warrants and Desler receiving 2,500,000 warrants, both exercisable at 0.28 pence.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
Directorate Change
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
Details of the votes received will be available on the Company's website shortly.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 577,500,000 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.28 pence per Ordinary Share and are exercisable at any time until the third anniversary of date of grant.
In addition, the Company has issued 53,750,000 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of date of grant.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7.00 a.m. on 15 May 2026.
Directorate Change
The Company announces that Cathy Tralau-Stewart did not stand for re-election as a Non-Executive Director at the Company's AGM held earlier today. Accordingly, following the conclusion of the AGM, Cathy has stepped down from the Board with immediate effect.
The Board would like to thank Cathy for her valuable contribution to the Company during her tenure and wishes her every success in the future.
Cathy Tralau-Stewart commented:
"I am committed to supporting the broader translation of academic science to patients and as such I think my time is best spent focusing on my leadership of the Milner Therapeutics Institute, University of Cambridge.
I am confident in the current management and scientific teams and that focusing the portfolio on later stage pre-clinical projects is important for the Company to deliver for shareholders.
I wish ValiRx and the team the best for the future."
Martin Gouldstone, Non-Executive Chairman of ValiRx commented:
"On behalf of the Board of VAL plc I would like to say a big thank you to Cathy for her scientific leadership in both her roles as CSO and more recently on the Board. Cathy leaves VAL in a much stronger position scientifically. We wish her well as she concentrates on her executive role at the Milner Therapeutics Institute."
The Directors of the Company take responsibility for this announcement.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/yzY60P | |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com | |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 | |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 | |
| V Formation (Public Relations) Jocelyn Braithwaite | +44 (0) 115 646 5491 www.vformation.co.uk/ jocelyn@vformation.co.uk | |
| Subscribe to our news alert service: https://valirx.com/s/f298d1 | ||
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Warrants as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 0.28 pence | 25,000,000 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Gerry Desler |
| 2 | Reason for notification | |
| a. | Position/Status | Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Warrants as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 0.28 pence | 2,500,000 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.